Skip to content
Open access

Impact of Implementing Alternative Human Papillomavirus (HPV) Vaccination Strategies in Kenya: A Modeling Study

Jan 2026 · MDM Policy & Practice · Vol 11 · 0 citations · 54 references
Medicine

Abstract

Background: Implementation delays reduce population-level effects of evidence-based interventions. We conducted a modeling study to estimate the effect of priority policy decisions on a human papillomavirus (HPV) vaccination program in Kenya. Methods: We used a static cohort model to estimate the health effects and costs of introduction and 1-dose switch delays, switching to nonavalent vaccine (9vHPV), supply disruptions, and various scale-up scenarios. Costs were evaluated from the health system perspective. We estimated cervical cancer cases, deaths, disability-adjusted life-years (DALYs), and program and health care costs. Results: Compared with no vaccination, maintaining current program performance would avert approximately 173,000 (95% UI: 149,000–191,000) cases and 2.7 (2.3–3.0) million DALYs across 2019 to 2100. A gradual scale-up of the current 2-dose quadrivalent vaccine (4vHPV) program would avert an additional 16,000 (14–18,000) cases (9%), increasing to 33,000 (28–37,000) cases (19%) if a multiage catchup is implemented in 2030. Accelerated scale-up of 1-dose bivalent vaccine (2vHPV) would avert 184,000 (164–199,000) cases and 3.0 (2.6–3.2) million DALYs, compared with no vaccination; translating to an additional 11,000 (2–17,000) cases averted (6%) compared with maintaining a 2-dose strategy, but at lower program ($81 million vs $76 million) and treatment costs ($2.09 billion vs $2.07 billion). HPV vaccination introduction in 2015 rather than 2019 would have averted an additional 74,000 (43%) cases. Annual vaccine supply disruptions translates to less than 9,000 (200–16,000) cases (5%) and 212,000 (74–305,000) DALYs averted (7%) compared with a 1-dose strategy. A 1-dose 9vHPV strategy would have more health benefits and save additional treatment costs compared with a 1-dose 2vHPV vaccine. Conclusions: Prompt 1-dose switch and rapid scale-up and adoption of a 9vHPV program should be priority policy decisions for Kenya. Graphical abstract

Read PDF

Similar papers

Review Open access Aug 2026

Real-World Effectiveness and Impact of Human Papillomavirus Vaccination in Males: A Comprehensive Review.

Real-world evidence indicates that HPV vaccination substantially reduces anogenital and oral HPV infections and AGW in males, reinforcing the public health significance of universal HPV vaccination programs worldwide.

Andres Manrique, Bekana K. Tadese, Yushi Huang et al. · 0 citations
Open access Jul 2026

Evaluating the cost-effectiveness of implementing HPV vaccination in Turkiye's National Immunization Program using the PRIME model.

Findings from this analysis support the inclusion of HPV vaccination within the National Immunization Program (NIP) as a cost-effective public health strategy capable of reducing the burden of cervical cancer.

Erhan Ersoy, Ali Gursoy, Husna Guder · 0 citations
Review Aug 2026

Missed Opportunities for Human Papillomavirus Vaccine Prescription in French Military Primary Care: A KAP Survey With Scenario-Based Modeling.

In SSA primary care, routine initiation of HPV vaccination via prescription appears constrained mainly by missed opportunities and organizational friction rather than clinician opposition, with additive effects when combining levers.

Pierre-Louis Conan, B. Buch, E. le Dault et al. · 0 citations
Review Aug 2026

Effects of School-Entry Vaccination Mandates on Adolescent Human Papillomavirus Vaccination Uptake: United States, 2008-2023.

Although mandates alone are unlikely to achieve national HPV vaccination targets, they may serve as an important component of comprehensive state efforts to increase uptake and prevent HPV-related cancers.

Angela W. Chen, Edwin S. Wong, Rachel L. Winer et al. · 0 citations
Jul 2026

Cost-Effectiveness of an HPV Vaccination Program in the Postpartum Period.

A postpartum HPV vaccination program is a cost-effective strategy to reduce cervical dysplasia and cancer, meeting standards for preventative care and intervention and meeting standards for preventative care and intervention.

Ava D. Mandelbaum, C. G. Nguyen, Ross Harrison et al. · 0 citations
Open access Jul 2026

Health economic impact and cost threshold for switching from bivalent to nonavalent HPV vaccination for preadolescent girls in KwaZulu Natal, South Africa: A mathematical modeling analysis accounting for the HIV epidemic.

Implementing 9vHPV can result in a greater reduction in cervical cancer burden than 2vHPV, but vaccine costs need to be reduced for 9vHPV to be cost-effective in KwaZulu-Natal.

Christine L. Hathaway, Jacinda Tran, C. van Schalkwyk et al. · 0 citations

We use cookies to run the site and, with your consent, for analytics and to show ads. See our Cookie Policy.